Benzinga | Jan 25, 2021 07:46AM EST

BMO Capital Downgrades Alnylam Pharmaceuticals to Market Perform, Announces $185 Price Target

BMO Capital analyst Do Kim downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Outperform to Market Perform and announces $185 price target.